Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2020 | CASSIOPE: cabozantinib in the real-word for RCC

Michael Staehler • 15 Feb 2020
GU Cancers 2020
Genitourinary Cancer Kidney Cancer Cabozantinib
CASSIOPE

Michael Staehler, MD, PhD, Ludwig Maximilian University of Munich, Munich, Germany, discusses the CASSIOPE study (NCT03419572), assessing the use of cabozantinib for the treatment of advanced renal cell carcinoma (RCC). This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.

More from Michael Staehler

0:46
Kidney cancer: where are we now, where are we going?
Michael Staehler • 15 Feb 2020
1:12
Papillary kidney cancer: prognosis & therapy efficacy
Michael Staehler • 16 Feb 2020

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
0:45
SYNC-T combination immunotherapy in mCRPC
George Prendergast • 8 Apr 2024
0:40
PSMA PET findings in 225AC-J591-treated patients with mCRPC
Andres Ricaurte-Fajardo • 9 Apr 2024
0:45
Should radioligand therapies be used in earlier settings in prostate cancer?
Andres Ricaurte-Fajardo • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals